Skip to main content

Another Asbestos-in-Talc Lawsuit Ends in a Mistrial

Another Asbestos-in-Talc Lawsuit Ends in a Mistrial

Another Asbestos-in-Talc Lawsuit Ends in a Mistrial

Introduction

This is the second time in two weeks that a talcum powder lawsuit has ended in a mistrial. On Tuesday, October 3, 2018, a Los Angeles jury was dismissed as the judge agreed that they failed to arrive at a unanimous decision and were incapable of announcing a verdict in a lawsuit filed by a plaintiff.

The plaintiff who formerly worked as a computer salesman claimed he was diagnosed with mesothelioma due to asbestos exposure. The jury hoped for at least nine votes to reach a conclusion but was stuck with eight to four against Johnson & Johnson.  

Talcum powder lawsuits are currently underway in several state courts across the nation. All with a similar allegation that the asbestos-exposure from talcum use causes mesothelioma and ovarian cancer. The multidistrict litigation (MDL 2738; In Re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices, and Products Liability Litigation) is presided over by Hon. Freda L. Wolfson, U.S.D.J./ Hon. Lois H. Goodman for coordinated pretrial proceedings in the District of New Jersey.

Last month, J&J's Talc supplier Imerys Talc America has agreed to settle the claims made by a plaintiff that years of using their asbestos-contaminated Baby Powder caused her mesothelioma.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Attorneys Seek Reconsideration of Talc MDL Daubert Ruling

Categories: General

Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…

Philips resolves DreamStation suits for $1.1B

Categories: Settlements

Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…

FDA OKs Generic OTC Naloxone Spray Approved by FDA

Categories: FDA Related

The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.

Our Legal Drafting Services    
start @ $25 per hour.